Brokerages Set Repligen Corporation (NASDAQ:RGEN) Target Price at $166.15

Shares of Repligen Corporation (NASDAQ:RGEN) have earned an average recommendation of “Moderate Buy” from the fifteen brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, ten have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $166.1538.

Several research firms recently issued reports on RGEN. HC Wainwright increased their target price on Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Royal Bank Of Canada assumed coverage on Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 target price on the stock. Roth Mkm assumed coverage on Repligen in a research report on Friday, April 17th. They issued a “buy” rating and a $160.00 price target on the stock. Wells Fargo & Company reduced their price target on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Finally, Rothschild & Co Redburn set a $160.00 price target on Repligen and gave the company a “buy” rating in a research report on Friday, April 17th.

Institutional Investors Weigh In On Repligen

A number of hedge funds have recently bought and sold shares of RGEN. Measured Wealth Private Client Group LLC acquired a new stake in shares of Repligen during the 3rd quarter worth about $29,000. Bayforest Capital Ltd acquired a new stake in shares of Repligen during the 4th quarter worth about $32,000. Rachor Investment Advisory Services LLC acquired a new stake in shares of Repligen during the 4th quarter worth about $33,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen during the 4th quarter worth about $36,000. Finally, Farther Finance Advisors LLC raised its position in shares of Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 128 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

NASDAQ RGEN opened at $123.95 on Wednesday. The stock has a market cap of $6.99 billion, a PE ratio of 137.72, a P/E/G ratio of 2.37 and a beta of 1.09. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $100.99 and a twelve month high of $175.77. The stock has a fifty day simple moving average of $117.94 and a 200-day simple moving average of $139.78.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. During the same quarter in the prior year, the company earned $0.39 EPS. Repligen’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities analysts anticipate that Repligen will post 1.99 earnings per share for the current year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.